Ilya Giverts

Ilya Giverts

Auto-generated profile, based on publicly available information

Ilya Giverts

The Mass General Brigham Heart and Vascular Institute, Massachusetts General Hospital, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2024 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
ASAnastasia Shchendrygina
Anastasia Shchendrygina
ARAmina Rakisheva
Amina Rakisheva
IGIlya Giverts
Ilya Giverts
YRYasmin Rustamova
Yasmin Rustamova
ASAnzhela Soloveva
Anzhela Soloveva
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity. Recently, GLP-1 RAs have garnered attention for their cardiovascular benefits beyond glycaemic control in patients with type 2 diabetes, exhibiting patterns previously seen in cardiovascular outcomes trials on sodium–glucose cotransporter 2 inhibitors, which now receive a high level of recommendation for the treatment of heart failure (HF). GLP-1 RAs have been increasingly investigated in HF cohorts, but mainly in small-scale studies reporting inconclusive findings regarding clinical outcomes and different safety profiles in HF patients with reduced and preserved ejection fractions. This review discusses the effects of GLP-1 RAs on surrogate HF outcomes, such as cardiac structure and function, exercise capacity and quality of life, in HF patients across the spectrum of left ventricular ejection fraction, to provide insights into the potential of these agents to be investigated in large clinical trials to evaluate clinical outcomes.

1 January 2024 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
ARAmina Rakisheva
Amina Rakisheva
ASAnzhela Soloveva
Anzhela Soloveva
ASAnastasia Shchendrygina
Anastasia Shchendrygina
IGIlya Giverts
Ilya Giverts
Rakisheva A, et al. Int J Heart Fail. 2024 Jul;6(3):93-106. https://doi.org/10.36628/ijhf.2023.0064

1 August 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
CICatherine G. Ireland
Catherine G. Ireland
DBDanielle S. Burstein
Danielle S. Burstein
SDSharlene M. Day
Sharlene M. Day
ARAnna Axelsson Raja
Anna Axelsson Raja
MRMark W. Russell
Mark W. Russell
CHCarolyn Y. Ho
Carolyn Y. Ho
BACKGROUND: The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being. METHODS: VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) participants with early stage sarcomeric HCM (primary analysis cohort) and subclinical HCM (sarcomere variant without left ventricular hypertrophy comprising the exploratory cohort) who completed baseline and year 2 HRQOL assessment via the pediatric quality of life inventory and CPET were studied. Metrics correlating with baseline HRQOL and CPET performance were identified. The impact of valsartan treatment on these measures was analyzed in the early stage cohort. RESULTS: Two hundred participants were included: 166 with early stage HCM (mean age, 23±10 years; 40% female; 97% White; and 92% New York Heart Association class I) and 34 subclinical sarcomere variant carriers (mean age, 16±5 years; 50% female; and 100% White). Baseline HRQOL was good in both cohorts, although slightly better in subclinical HCM (composite pediatric quality of life score 84.6±10.6 versus 90.2±9.8; P =0.005). Both cohorts demonstrated mildly reduced functional status (mean percent predicted peak oxygen uptake 73±16 versus 78±12 mL/kg per minute; P =0.18). Percent predicted peak oxygen uptake and peak oxygen pulse correlated with HRQOL. Valsartan improved physical HRQOL in early stage HCM (adjusted mean change in pediatric quality of life score +4.1 versus placebo; P =0.01) but did not significantly impact CPET performance. CONCLUSIONS: Functional capacity can be impaired in young, healthy people with early stage HCM, despite New York Heart Association class I status and good HRQOL. Peak oxygen uptake was similarly decreased in subclinical HCM despite normal left ventricular wall thickness and excellent HRQOL. Valsartan improved physical pediatric quality of life scores but did not significantly impact CPET performance. Further studies are needed for validation and to understand how to improve patient experience. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01912534.

5 May 2026 in Circulation
Verified
Journal Article
Open access
ILIsabela Landsteiner
Isabela Landsteiner
LSLindsey K. Stolze
Lindsey K. Stolze
TPTess E. Peterson
Tess E. Peterson
APAndrew Perry
Andrew Perry
PLPhillip Lin
Phillip Lin
GLGregory D. Lewis
Gregory D. Lewis
BACKGROUND: Exercise unmasks limitations in multiorgan system reserve capacity characteristic of heart failure with preserved ejection fraction (HFpEF). However, the metabolic and genetic underpinnings of exercise deficits and their cumulative contribution to HFpEF severity and prognosis remain incompletely understood. METHODS: We used invasive cardiopulmonary exercise testing, metabolite profiling, and genomics to simultaneously characterize 7 exercise physiological deficits in patients with HFpEF: reduced exercise stroke volume and heart rate, steep pulmonary capillary wedge pressure/cardiac output slope, elevated pulmonary vascular resistance, pulmonary mechanical limitation to exercise, impaired peripheral oxygen extraction, and obesity-related exaggerated metabolic cost of initiating exercise. We first mapped the distribution, functional, and prognostic significance of these exercise deficits. We then applied least absolute shrinkage and selection operator regression to identify metabolite signatures of each exercise deficit and measured the relation of these signatures with clinical-demographic features, cardiac magnetic resonance imaging, and incident heart failure in 6345 individuals in the MESA study (Multi-Ethnic Study of Atherosclerosis) with ≈20 years of follow-up. Last, we mapped deficit-implicated metabolites to tissue-specific genetic variation in ≈2 million individuals, including ≈153 000 with heart failure, leveraging the largest genome-wide association studies of HFpEF comorbidities (obesity, renal disease, diabetes) to evaluate shared metabolic mechanisms of HFpEF pathophysiology. RESULTS: Our invasive cardiopulmonary exercise testing HFpEF cohort (age, 61.7±14.1 years; 54% female; body mass index, 30.6±6.7 kg/m 2 ) exhibited a broad range of compound cardiac and extracardiac exercise deficits. Individuals with ≥5 exercise deficits had a nearly 4-fold higher hazard of incident cardiovascular event or mortality (hazard ratio, 3.90 [95% CI, 1.74–8.75]; P <0.0001). The metabolite signature of exercise pulmonary capillary wedge pressure/cardiac output slope conferred a hazard ratio of 1.43 per 1-SD increment (95% CI, 1.20–1.71; P <0.001) for incident heart failure in MESA. Addition of all invasive cardiopulmonary exercise testing deficit metabolic signatures in a single model yielded ≈20% continuous net reclassification improvement over traditional HFpEF risk factors. Genes implicated by the exercise deficit metabolome were enriched in the heart failure genome-wide association study (≈2 million) and shared with obesity, renal dysfunction, and diabetes, highlighting a lifelong shared predisposition to heart failure (including HFpEF) and its comorbidities. CONCLUSIONS: Organ-specific responses to exercise and their circulating metabolite signatures are strongly linked to HFpEF development and prognosis. These results offer a paradigm for parsing HFpEF subphenotypes and prioritizing metabolic mechanisms of HFpEF.

5 September 2025 in Circulation
Verified
Journal Article
Open access
JCJoseph Campain
Joseph Campain
CGCatharine Griskowitz
Catharine Griskowitz
CNChloe Newlands
Chloe Newlands
BCBrian L. Claggett
Brian L. Claggett
IKIan J. Kulac
Ian J. Kulac
GLGregory D. Lewis
Gregory D. Lewis
BACKGROUND: Post-exercise oxygen uptake recovery (VO 2 Rec) is slow in advanced heart failure. We sought to establish easily derived VO 2 Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VO 2 Rec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy. METHODS: VO 2 Rec patterns were evaluated in relation to cardiac performance and the primary outcome of heart failure hospitalization death in a referral cohort with dyspnea on exertion undergoing cardiopulmonary exercise testing with hemodynamic monitoring (MGH-ExS [Massachusetts General Hospital Exercise Study]). We then investigated longitudinal measures of VO 2 Rec in the pivotal phase 3 randomized controlled trial SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in Hypertrophic Cardiomyopathy) of aficamten versus placebo for 24 weeks in participants with symptomatic obstructive hypertrophic cardiomyopathy. For both cohorts, VO 2 Rec was uniformly measured as time for VO 2 to decline by >0%, 12.5% (VO 2 T 12.5% ), 25%, and 50% of peak VO 2 . RESULTS: Among 814 MGH-ExS patients (58±16 years of age, 58% women), those with a longer VO 2 T 12.5% (≥35 versus <35 seconds) demonstrated elevated exercise pulmonary capillary wedge pressure to cardiac output slope ( P <0.0001) with no difference in peripheral oxygen extraction ( P =0.11). For each 15-second increase in VO 2 T 12.5% , the hazard ratio for heart failure hospitalization and all-cause death was 1.54 (95% CI, 1.35–1.76; P <0.001). In SEQUOIA-HCM participants with cardiopulmonary exercise testing at baseline and week 24 (n=263, 59.1±2.9 years of age, 41% women), baseline VO 2 T 12.5% was 45±20 seconds and improved 8 seconds (95% CI, −12 to −5 seconds; P <0.001) with aficamten treatment compared with placebo at 24 weeks. Participants treated with aficamten versus placebo were more likely to improve VO 2 T 12.5% by ≥15 seconds (odds ratio [OR], 3.7 [95% CI, 1.9–6.9]; number needed to treat=4.8). Shortening of VO 2 T 12.5% correlated with reduced NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity cardiac troponin I, and left ventricular outflow tract gradient (all P <0.005). CONCLUSIONS: This study established VO 2 T 12.5% as a new measure that reflects cardiac performance during exercise and predicted heart failure event-free survival. Furthermore, VO 2 T 12.5% improved proportional to improvements in left ventricular outflow tract gradient and cardiac biomarkers in response to aficamten treatment, a cardiospecific therapy for obstructive hypertrophic cardiomyopathy. The simplicity and physiological relevance of VO 2 T 12.5% support its regular inclusion in cardiopulmonary exercise testing protocols evaluating cardiac function during exercise. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05186818.

11 November 2024 in European Cardiology Review
Verified
Journal Article
Open access
PDF file
ASAnastasia Shchendrygina
Anastasia Shchendrygina
IGIlya Giverts
Ilya Giverts
MTMariya Tokmakova
Mariya Tokmakova
EKEkaterina Kharchenko
Ekaterina Kharchenko
AVAlisa Vlasova
Alisa Vlasova
NMNadezda Mukhina
Nadezda Mukhina
The management of heart failure with preserved ejection fraction (HFpEF) remains largely unresolved due to our limited understanding of the underlying mechanisms of the pathology and the challenges in accurately phenotyping this heterogeneous syndrome. A paradigm shift is required to personalise care and unify our approaches to HFpEF patients for future clinical trials. Accordingly, we propose a staging classification for HFpEF based on the identification of the involved cardiac chambers by echocardiography.